Moderna shares plunge on cancer vaccine data leak
Moderna shares fell more than 25% and Merck shares dropped over 3% after preliminary Phase 3 results for their experimental personalized cancer vaccine were apparently published early. The trial found that combining the vaccine with… Keytruda reduced melanoma recurrence or death risk by 42% compared with Keytruda alone, with no new safety concerns reported. Merck confirmed the key findings, though it said it is too early to assess the treatment’s effect on overall survival.